HEALTH CARE:
HEALTH CARE SERVICES
SIC: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Beam Therapeutics Inc. operates as a biotechnology company. The Company develops DNA base editing technologies for the treatment of human diseases. Beam Therapeutics serves customers in the State of Massachusetts.
Market Cap | 2.469 Billion | Shares Outstanding | 34.311 Million | Avg 30-day Volume | 0 | ||
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | 0.482 | ||
Price/Sales | 5.63 | Debt to Equity | 1.86 | EBITDA | 97.878 Million | ||
Price to Book Value | 6.23 | Forward PE | Enterprise Value | 2.537 Billion | |||
Total Cash | 90.229 Million | Current Debt | 68.012 Million | Gross Profit | 270.939 Million | ||
BETA | 0.0 | 52-week High/Low | 0.0 / 0.0 | Next Earnings Date | 2021-02-25 | Price to Cash FLow (P/CF) | |
Data provided by IEX Cloud |
Q4 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|---|---|---|---|---|---|
In top 10: | 6 | 2 | 200.0% | 4 (0.24%) | 1 (0.06%) | 300.0% |
Funds Holding: | 236 | 208 | 13.46% | 65 (3.91%) | 55 (3.42%) | 18.18% |
13F shares: | 31.941 Million | 32.638 Million | -2.14% | 12.468 Million | 12.711 Million | -1.91% |
% Ownership | 93.093 | 95.2638 | -2.28% | 36.3396 | 37.101 | -2.05% |
New Positions: | 66 | 30 | 120.0% | 25 | 13 | 92.31% |
Increased Positions | 55 | 72 | -23.61% | 10 | 15 | -33.33% |
Closed Positions | 37 | 34 | 8.82% | 14 | 7 | 100.0% |
Reduced Positions | 87 | 80 | 8.75% | 24 | 20 | 20.0% |
Total Calls | 718.906 Thousand | 346.828 Thousand | 107.28% | 408.6 Thousand | 159.3 Thousand | 156.5% |
Total Puts | 366.607 Thousand | 160.995 Thousand | 127.71% | 85.8 Thousand | 8.1 Thousand | 959.26% |
PUT/CALL Ratio | 0.51 | 0.46 | 10.87% | 0.21 | 0.05 | 320.0% |
1 hedge funds and active managers as identified by whalewisdom.com through public filings. |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2021-02-09 | 2 | |
|
176,905 | 2021-02-09 | 2 | |
|
0 | 2021-02-09 | 2 | |
GETZ HEATHER C EVP, CFO & CAO |
|
0 | 2021-02-09 | 1 |
CAPPER JOSEPH H PRESIDENT & CEO |
|
0 | 2021-02-09 | 1 |
|
0 | 2021-02-09 | 2 | |
BROADWAY FRED PRESIDENT BIOTEL HEART |
|
0 | 2021-02-09 | 1 |
|
0 | 2021-02-09 | 2 | |
|
0 | 2021-02-09 | 2 | |
|
0 | 2021-02-09 | 2 | |
|
0 | 2021-02-09 | 2 | |
|
0 | 2021-02-09 | 2 | |
WADHWA MANISH SVP & CMO |
|
0 | 2021-02-09 | 1 |
STOICA ANDREI G SVP & CTO |
|
0 | 2021-02-09 | 1 |
WISNIEWSKI DANIEL SVP, TECHNICAL OPERATIONS |
|
24,817 | 2020-02-18 | 0 |
FEROLA PETER SVP & GENERAL COUNSEL |
|
8,507 | 2019-12-31 | 0 |
HRENKO GEORGE SVP - HUMAN RESOURCES |
|
20,518 | 2017-02-27 | 0 |
GELDART MICHAEL SENIOR VICE PRESIDENT |
|
65,396 | 2015-06-17 | 0 |
|
196,670 | 2015-04-30 | 0 | |
|
129,174 | 2014-05-05 | 0 | |
MCNAMARA ANNA SENIOR VICE PRES/CLINICAL OP. |
|
90,903 | 2013-02-19 | 0 |
GROPPER CHARLES SENIOR VICE PRESIDENT |
|
51,422 | 2012-02-21 | 0 |
SCHULER ANTHONY SENIOR VICE PRESIDENT |
|
25,121 | 2012-02-21 | 0 |
KASRAWI JAREER SENIOR VICE PRESIDENT |
|
26,075 | 2012-02-21 | 0 |
|
264,766 | 2011-05-02 | 0 | |
LEONE PHILIP SENIOR VICE PRESIDENT |
|
43,655 | 2011-03-04 | 0 |
|
256,902 | 2010-05-10 | 0 | |
IMPERATO JOHN F SENIOR VICE PRESIDENT |
|
39,179 | 2010-05-10 | 0 |
MARGOLIES MATTHEW SENIOR VICE PRESIDENT, SALES |
|
27,381 | 2010-05-10 | 0 |
GALVAN MARTIN P CHIEF FINANCIAL OFFICER |
|
21,019 | 2009-10-23 | 0 |
|
9,614 | 2009-01-22 | 0 | |
|
635,966 | 2008-08-06 | 0 | |
|
No longer subject to file | 2008-08-06 | 0 | |
SANDERLING VENTURE PARTNERS IV, L.P. SANDERLING VENTURES MANAGEMENT V SANDERLING VENTURES MANAGEMENT VI SANDERLING VI LIMITED PARTNERSHIP SANDERLING VENTURE PARTNERS VI CO INVESTMENT FUND LP SANDERLING VI BETEILIGUNGS GMBH & CO KG SANDERLING V BETEILIGUNGS GMBH & CO KG SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP |
|
944,366 | 2008-08-06 | 0 |
SANDERLING VENTURE PARTNERS IV, L.P. SANDERLING VENTURES MANAGEMENT IV SANDERLING (FERI TRUST) VENTURE PARTNERS IV, L.P. SANDERLING IV LIMITED PARTNERSHIP SANDERLING IV BIOMEDICAL CO INVESTMENT FUND L P SANDERLING IV BIOMEDICAL L P |
|
631,829 | 2008-08-06 | 0 |
SANDERLING VENTURE PARTNERS IV, L.P. SANDERLING V BETEILIGUNGS GMBH & CO KG SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP |
|
716,018 | 2008-03-25 | 0 |
SANDERLING VENTURE PARTNERS IV, L.P. SANDERLING VENTURES MANAGEMENT IV SANDERLING VENTURES MANAGEMENT V SANDERLING VENTURES MANAGEMENT VI SANDERLING VI LIMITED PARTNERSHIP |
|
357,461 | 2008-03-25 | 0 |
SANDERLING VENTURE PARTNERS IV, L.P. SANDERLING IV LIMITED PARTNERSHIP SANDERLING (FERI TRUST) VENTURE PARTNERS IV, L.P. SANDERLING IV BIOMEDICAL CO INVESTMENT FUND L P SANDERLING IV BIOMEDICAL L P |
|
1,484,576 | 2008-03-25 | 0 |
GUIDANT INVESTMENT CORP |
|
No longer subject to file | 2008-03-25 | 0 |
COHEN ARIE PRESIDENT AND CEO |
|
0 | 2008-03-18 | 0 |
GEROLAMO EMMANUEL SENIOR VP SALES & MARKETING |
|
0 | 2008-03-18 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Enhanced Index Plus Fund | BEAT | -152.0 shares, $-5853.52 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Defensive Long Fund | BEAT | -11.0 shares, $-423.61 | 2020-03-31 | N-PORT |
INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund | BEAT | -861.0 shares, $-62060.88 | 2020-12-31 | N-PORT |
FundVantage Trust- Gotham Index Plus All-Cap Fund | BEAT | -153.0 shares, $-5892.03 | 2020-03-31 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | BEAT | -800.0 shares, $-57664.0 | 2020-12-31 | N-PORT |
JPMorgan Trust I- JPMorgan Global Allocation Fund | BEAT | -21183.0 shares, $-1513737.18 | 2021-01-31 | N-PORT |
JPMorgan Trust I- JPMorgan Opportunistic Equity Long/Short Fund | BEAT | -142356.0 shares, $-10172759.76 | 2021-01-31 | N-PORT |